## **CLAIMS**

- 1. A novel pharmaceutical composition comprising of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof optionally with pharmaceutically acceptable excipients, wherein the said composition provides a gastrosparing effect and minimizes the gastric toxicity induced by the administration of nonsteroidal anti-inflammatory drug.
- 2. A composition according to claim 1, wherein the glycosaminoglycan is Chondroitin sulphate.

10

15

5

- A composition according to claims 1 and 2, wherein the nonsteroidal antiinflammatory drug is selected from a group comprising indomethacin,
  flurbiprofen, naproxen, diclofenac, ketorolac, mefenamic acid, ibuprofen,
  ketoprofen, meloxicam, piroxicam, nimesulide, celecoxib, rofecoxib,
  etoricoxib, parecoxib, valdecoxib, lumiracoxib, or salts thereof.
- 4. A composition according to claims 1-3, wherein the ratio of glycosaminoglycan or salts thereof and nonsteroidal anti-inflammatory drug or salts thereof is from 100:1 to 1:100.

20

25

5. A composition according to claims 1-4, wherein the pharmaceutically acceptable excipients are selected from a group comprising diluents, disintegrants, fillers, bulking agents, vehicles, pH adjusting agents, stabilizers, anti-oxidants, binders, buffers, lubricants, antiadherants, coating agents, preservatives, emulsifiers, suspending agents, release controlling agents, polymers, colorants, flavoring agents, plasticizers, solvents, preservatives,

WO 2005/067943 PCT/IN2005/000026

glidants, chelating agents and the like; used either alone or in combination thereof.

- 6. A composition according to claims 1-5, which is formulated as oral dosage forms such as tablets, pills, capsules, gels, finely divided powders, dispersions, suspensions, solutions, emulsions, etc; pulmonary and nasal dosage form such as sprays, aerosols, etc.; topical dosage forms such as gels, ointments, creams, etc; parenteral dosage forms; controlled release formulations; fast melt formulations, lyophilized formulations, delayed release formulations, sustained release, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.
- 7. A process for preparing a pharmaceutical composition according to claim 1, which comprises mixing of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof optionally with pharmaceutically acceptable excipients and formulating into a suitable dosage form.
- 8. A process according to claim 7, wherein the glycosaminoglycan is Chondroitin sulphate.
  - 9. A process according to claims 7 and 8, wherein the nonsteroidal antiinflammatory drug is selected from a group comprising indomethacin,
    flurbiprofen, naproxen, diclofenac, ketorolac, mefenamic acid, ibuprofen,
    ketoprofen, meloxicam, piroxicam, nimesulide, celecoxib, rofecoxib,
    etoricoxib, parecoxib, valdecoxib, lumiracoxib, licofelone, or salts thereof.

25

WO 2005/067943 PCT/IN2005/000026

10. A process according to claims 7-9, wherein the ratio of glycosaminoglycan or salts thereof and nonsteroidal anti-inflammatory drug or salts thereof is from 100:1 to 1:100.

- 5 11. A method of providing a gastrosparing effect and minimizing the gastric toxicity induced by the administration of nonsteroidal anti-inflammatory drug by administering a pharmaceutical composition comprising of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof optionally with pharmaceutically acceptable excipients.
  - 12. Use of a combination comprising of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof optionally with pharmaceutically acceptable excipients, for preparing a composition for a gastrosparing effect and minimizing the gastric toxicity induced by the administration of nonsteroidal anti-inflammatory drug.

15

25

- 13. A composition comprising of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof, as herein described and illustrated by the examples.
  - 14. The process for the preparation of a composition comprising of glycosaminoglycan or salts thereof and at least one nonsteroidal anti-inflammatory drug or salts thereof, as herein described and illustrated by the examples.